Tokyo Joe's Cafe / Societe Anonyme/No Pennies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KZAP who wrote (55144)	2/11/1999 11:02:00 PM
From: hoffy	Read Replies (2) of 119973

KZAP: Why do like ANTX? Can you give some details about them. For tomorrow IMCL is the PLAY though with the late news reported today: In case anyone missed it here it is: Biotech company ImClone's (IMCL) chief financial officer said the company's lead anti-cancer drug, C225, is heading into Phase III trials in the next few weeks. In previous trials, Carl Goldfisher said, the drug was "remarkably safe" C225 serves as an antibody to block epidermal growth factor receptor, the market for which is in "the hundreds of millions of dollars," Goldfisher told an audience at the Cruttenden Roth Growth Stock Conference. The company will soon start to build a manufacturing plant with funding it received from Merck and will start producing C225, assuming Food and Drug Administration approval, in 18 months to two years.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next